Toshinari Yamashita

Jun 24, 2024 | nature.com | Yeon Hee Park |David Sommerhalder |Kan Yonemori |Erika Hamilton |Toshinari Yamashita |Rachel M. Layman | +3 more

Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03060-0, published online 1 June 2024In the version of the article initially published, in Extended Data Fig. 1, under “Part 1B”, “5 mg QD” originally read “3 dose levels” and “n=9” was missing from that box. There was originally an additional “Cohort 1 (5 mg QD, n=9)” box that has now been removed. Under “Part “2A”, the text “fulvestrant 500 mg” originally preceded “(n=35)”. In Extended Data Fig.

Jun 1, 2024 | nature.com | Yeon Hee Park |David Sommerhalder |Kan Yonemori |Erika Hamilton |Toshinari Yamashita |Rachel M. Layman | +3 more

AbstractInhibition of histone lysine acetyltransferases (KATs) KAT6A and KAT6B has shown antitumor activity in estrogen receptor-positive (ER+) breast cancer preclinical models. PF-07248144 is a selective catalytic inhibitor of KAT6A and KAT6B.

Apr 29, 2024 | touchoncology.com | Toshinari Yamashita

Breast Cancer Read Time: 12 mins Copy Link Published Online: Apr 29th 2024 touchREVIEWS in Oncology & Haematology. 2024;20(1):1–4:Online ahead of journal publication Authors: Toshinari Yamashita Quick Links: Overview Trastuzumab deruxtecan (T-DXd) is an antibody–drug conjugate widely used in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC), based on the results of the DESTINY-Breast 01, 02 and 03 studies.